CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) Director Chee Kong Choo purchased 112,000 shares of CytoMed Therapeutics stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $1.15 per share, with a total value of $128,800.00. Following the completion of the purchase, the director owned 430,324 shares in the company, valued at approximately $494,872.60. This trade represents a 35.18% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
CytoMed Therapeutics Price Performance
GDTC stock opened at $1.14 on Monday. CytoMed Therapeutics Limited has a 12 month low of $0.68 and a 12 month high of $3.68. The firm has a 50 day simple moving average of $1.04 and a 200 day simple moving average of $1.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17.
CytoMed Therapeutics (NASDAQ:GDTC – Get Free Report) last released its earnings results on Sunday, February 15th. The company reported ($0.06) EPS for the quarter. The company had revenue of $0.06 million for the quarter.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on CytoMed Therapeutics
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.
Read More
- Five stocks we like better than CytoMed Therapeutics
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
